A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Fondazione Italiana Linfomi - ETS
OHSU Knight Cancer Institute
Mayo Clinic
French Innovative Leukemia Organisation
Gruppo Italiano Malattie EMatologiche dell'Adulto
OHSU Knight Cancer Institute
PETHEMA Foundation
Jonsson Comprehensive Cancer Center
OHSU Knight Cancer Institute
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute